HOPKINTON — The town was quick to cut off a tax break deal with Lonza Biologics last year when the company announced it was shutting down, but has not pursued any paybacks for the lost tax revenue.

Town Manager Norman Khumalo confirmed the town hasn't looked into any options to recoup the money from the Swiss pharmaceutical supplier.

"At this point, we haven’t discussed that," he said.

The deal, known as a tax increment financing agreement, was approved in June 2007 and terminated last year by selectmen. The eight-year deal called for the company to retain 130 jobs, create 300 new jobs and invest $70 million into the building and equipment.

The town received a letter on July 18 saying the state’s Economic Assistance Coordinating Council voted to decertify the company on Dec. 18, 2013. The state doesn’t hold companies responsible for any repayments, according to Matt Sheaff, a housing and economic development spokesman.

These types of tax deals only apply to new construction.

Much of the planned construction to expand the building to 63,600-square-feet never materialized putting into question how much the town actually lost. Khumalo said an estimate has never been calculated.

Lonza announced last year that it plans to lay off approximately 200 employees and eventually close the South Street facility in a global downsizing of its microbial biologics facilities.

In Oct. 2012, the town reached a $450,000 settlement with Stryker Biotech, also on South Street, over its violation of a similar tax break agreement after the company pledged to bring 195 jobs within five years.

Khumalo said the circumstances with Lonza are different. As part of the investments made by the company the town received state funds for a $2.5 million sewer project, he said.

Jonathan Phelps can be reached at 508-626-4338 or jphelps@wickedlocal.com. Follow him on Twitter @JPhelps_MW.